That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Copyright 2024 The Associated Press. All Rights Reserved. FILE - A Coca-Cola sign is shown in San Francisco, Tuesday, Oct. 27, 2020. (AP Photo/Jeff Chiu,File) FILE ...

Biogen Inc. ( (BIIB)) has realeased its Q3 earnings. Here is a breakdown of the information Biogen Inc. presented to its investors. Biogen Inc. is a leading biotechnology company that specializes ...

Conservators in Florida spent seven months cleaning, drying and preserving two rare “onion bottles” that were likely made in England. Archaeologists were thrilled to discover the intact ...

At Bungalow, celebrity chef Vikas Khanna’s Indian restaurant in New York’s East Village, a dozen Indian single malt whiskies are spotlit in their own section on the spirits list. Just a few ...

Bio­gen’s in­vestors are grow­ing rest­less. Wednes­day’s third-quar­ter earn­ings call checked most of the box­es for a suc­cess­ful re­port. The com­pa­ny raised its full-year ...

My name is Cynthia, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Third Quarter 2024 Earnings Call and Business Update. All lines have ...

Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. But to truly unlock the amyloid-busting antibody’s potential, the company will ...

(Reuters) - Biogen (NASDAQ:BIIB) raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs. However ...